ATNM News and Press, Actinium Pharmaceuticals Inc. From 09/21/22

Actinium Pharmaceuticals Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update Highlighting Key Upcoming Milestones PR Newswire On track to report topline data from the Pivotal Phase 3 SIERRA trial for Iomab-B in Q4 2022 Overall survival data from...

Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference PR Newswire NEW YORK , Sept. 8, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the...

For further details see: Actinium started at buy at B Riley on bone marrow transplant conditioning therapy

Actinium Pharmaceuticals (ATNM) formal corporate presentation from NobleCon18 - Noble Capital Markets 18th Annual Small & Microcap Investor Conference - April 2022. Read More >>

Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cell...

Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation &a...

William Blair is maintaining Actinium Pharmaceuticals at outperform after the company's license and supply agreement with Immedica Pharma AB for Iomab-B. That agreement, announced Tuesday, provides Actinium (NYSE:ATNM) with a $35M upfront payment and up to $417M in  milestone payments. "...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, many of the top trending stocks are part of two distinct categories. Big news out of the pharmaceutical sector has several microcap biotech stocks in the green. Last week, Sunshine Biopharma  (NASDAQ: SBFM ...

Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...

Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...